abstract: The in vivo effects of patulin on hepatic monooxygenase enzymes in male @entity0 were examined after single and multiple exposures (i.p.) to the mycotoxin. The animals were exposed to a single dose of 1, 3 or 4.5 mg patulin/kg or daily doses of 1.0 mg/kg for 5 or 14 days. After single exposure no significant effect was observed on @entity3 hydroxylation while @entity4 hydroxylase increased significantly at 3 mg/kg and at 48 hr. The demethylation of @entity5 and @entity2 increased significantly 48 and 72 hr after 3.0 or 4.5 mg patulin/kg doses. A 12% increase was observed in cytochrome P-450 content 48 hr after exposure to 1 or 3 mg/kg. @entity1 -cytochrome C reductase was enhanced significantly at all 3 dose levels at 48 hr. At 24 hr hepatic @entity1 -dependent dehydrogenase activity increased 38 and 46% in animals exposed to a single dose of 3 mg patulin/kg, respectively. No effect of patulin was observed on the hepatic drug metabolizing enzymes examined except hexobarbital oxidation in @entity0 exposed to multiple doses of patulin. Patulin at best was a weak inducer of the hepatic mixed function oxidase system.

title: Effect of patulin on hepatic monooxygenase in male XXXX .

answer: @entity0


abstract: Three @entity0 with @entity2 and radial aplasia were examined at the Centre de G  n  tique M  dicale of Marsielles from 1974 to 1976. In each case the genetic basis of the @entity1 was discussed with the family at genetic counseling underlining the high risk of recurrence related to the autosomal recessive transmission. Each proband was the only @entity0 of the couple. In the first case the father and mother, each having one @entity0 from a previous marriage, decided to have no more @entity0 . In the second case, the use of fetoscopy and its limitations were discussed as another pregnancy was desired. However, the parents finally refused the procedure during pregnancy which yielded a second @entity0 with @entity5 who did not survive. In the third and most recent case the proband died. Since the young couple strongly desired another @entity0 , ultrasonic monitoring of pregnancy was cautiously suggested and its limitations clearly exposed. Echography was regularly repeated from the third month of pregnancy. The forearms were never detected on echography, nor on fetal radiography. Pregnancy was thus interrupted with @entity3 at 21 weeks gestational age. On examination the fetus presented bilateral aplasia of the forearm. Based on these observations, the authors discuss the problems raised by prenatal diagnosis of @entity4 .

title: [Prenatal diagnosis of XXXX ].

answer: @entity4


abstract: OBJECTIVES: The National @entity1 Institute (NCI) annually confirms therapy with treating physicians on a sample of @entity0 diagnosed with a specific @entity1 . METHODS: Using the NCI Patterns of Care data, treatment patterns were examined on a population-based sample of @entity0 diagnosed with @entity3 ( @entity3 ) in 2008. RESULTS: A random sample of 323 of 405 @entity3 @entity0 registered in SEER was selected. Most @entity0 had @entity2 , were >= 65   years, white, had private insurance, and treated in a hospital with a residency program. Surgery was primarily performed in @entity0 with non-metastatic disease (94%), in which: 26, 12, and 36% were at low, intermediate, and high-risk of recurrence, respectively. Amongst low-risk @entity0 ,    30% received adjuvant therapy. Amongst @entity0 at higher risk, 26-40% did not receive adjuvant therapy. @entity4 was the most common targeted therapy administered. On multivariate analysis, age and risk-group were associated with receipt of adjuvant targeted therapy. CONCLUSIONS: Our study shows that in 2008, the majority of @entity0 diagnosed with @entity3 received appropriate surgical and adjuvant therapies. However, a considerable subset may have been overtreated and undertreated. Future studies identifying factors that impact the delivery of adjuvant therapy should be conducted. J. Surg. Oncol. 2015 111:702-707.    2015 Wiley Periodicals, Inc.

title: XXXX : Treatment patterns of a population-based sample.

answer: @entity3


abstract: PURPOSE: Advanced imaging is commonly used for staging of @entity0 , despite recommendations against this practice. The objective of this study was to evaluate and compare use of imaging for staging of @entity0 in two integrated health care systems, Kaiser Permanente (KP) and Intermountain Healthcare (IH). We also sought to distinguish whether imaging was routine or used for diagnostic purposes. METHODS: We identified @entity1 with stages 0 to IIB @entity0 diagnosed between 2010 and 2012. Using KP and IH electronic health records, we identified use of computed tomography, positron emission tomography, or bone scintigraphy 30 days before diagnosis to 30 days postsurgery. We performed chart abstraction on a random sample of @entity1 who received a presurgical imaging test to identify indication. RESULTS: For the sample of 10,010 @entity1 , mean age at diagnosis was 60 years (range, 22 to 99 years); with 21% stage 0, 47% stage I, and 32% stage II. Overall, 15% of @entity1 (n = 1,480) received at least one imaging test during the staging window, 15% at KP and 14% at IH (P = .5). Eight percent of @entity1 received imaging before surgery, and 7% postsurgery. We found significant intraregional variation in imaging use. Chart abstraction (n = 129, 16% of @entity1 who received presurgical imaging) revealed that 48% of presurgical imaging was diagnostic. CONCLUSION: Use of imaging for staging of low-risk @entity0 was similar in both systems, and slightly lower than has been reported in the literature. Approximately half of imaging tests were ordered in response to a sign or symptom.

title: Use of imaging for staging of XXXX in two integrated health care systems: adherence with a choosing wisely recommendation.

answer: @entity0


abstract: Between January 1976 and March 1979, @entity4 was successfully repaired in six @entity0 with circular myotomy (Livaditis technique) and end-to-end @entity2 . @entity0 were 1 day-6 mo in age and weighed 2.4 to 8.0 kg at the time of repair. Four @entity0 required one and two @entity0 required two circular myotomies in the proximal esophagus to bridge gaps between esophageal ends, which varied from 1.2-3.0 cm. Follow-up has been 1-4 yr (mean-3 yr). Operative complications included: opening of the mucosa at myotomy (2) and @entity3 (2). Subsequently, three @entity0 developed anastomotic stricture which required dilatation. Current x-rays show ballooning of the esophagus at the myotomy site during swallowing in all. However, the esophageal diameter at the myotomy site was never more than 2 cm greater than that of the distal esophagus. In the three @entity0 with anastomotic stricture, mucosal ballooning was not greater than in the others. During follow-up, weights have ranged from the 3rd to the 50th percentile for age. Swallowing has been good in 4, fair in 1 (dilatation still required), and poor in 1 ( @entity1 necessitate @entity5 ). Circular myotomy offers a safe means of esophageal lengthening. Complications directly related to the myotomy are minimal (mucosal tear) and should be recognized at operation. Ballooning of the mucosa at the myotomy site is a common late finding but diverticulum formation has not occurred. Swallowing and esophageal motility are similar to other @entity0 who have had @entity4 repair.

title: Long-term follow-up circular myotomy for XXXX .

answer: @entity4


abstract: BACKGROUND AND OBJECTIVES: Evidence relating the rate of change in renal function, measured as @entity3 , after antihypertensive treatment in elderly @entity0 to clinical outcome is sparse. This study characterized the rate of change in @entity3 after commencement of antihypertensive treatment in an elderly population, the factors associated with @entity3 rate change, and the rate's association with all-cause and cardiovascular mortality. DESIGN, SETTING, @entity0 , _ MEASUREMENTS: Data from the Second Australian National Blood Pressure study were used, where 6083 @entity1 @entity0 aged >= 65 years were enrolled during 1995-1997 and followed for a median of 4.1 years (in-trial). Following the Second Australian National Blood Pressure study, @entity0 were followed-up for a further median 6.9 years (post-trial). The annual rate of change in the @entity3 was calculated in 4940 @entity0 using @entity4 measurements during the in-trial period and classified into quintiles (Q) on the basis of the following @entity3 changes: rapid decline (Q1), decline (Q2), stable (Q3), increase (Q4), and rapid increase (Q5). RESULTS: A rapid decline in @entity3 in comparison with those with stable eGFRs during the in-trial period was associated with older age, living in a rural area, wider pulse pressure at baseline, receiving diuretic-based therapy, taking multiple antihypertensive drugs, and having blood pressure <140/90 mmHg during the study. However, a rapid increase in @entity3 was observed in younger @entity0 and those with a higher @entity2 level. After adjustment for baseline and in-trial covariates, Cox-proportional hazard models showed a significantly greater risk for both all-cause (hazard ratio, 1.28; 95% confidence interval, 1.09 to 1.52; P=0.003) and cardiovascular (hazard ratio, 1.40; 95% confidence interval, 1.11 to 1.76; P=0.004) mortality in the rapid decline group compared with the stable group over a median of 7.2 years after the last @entity3 measure. No significant association with mortality was observed for a rapid increase in @entity3 . CONCLUSIONS: In elderly @entity0 with treated @entity1 , a rapid decline in @entity3 is associated with a higher risk of mortality.

title: Rate of Change in Renal Function and Mortality in Elderly Treated XXXX @entity0 .

answer: @entity1


abstract: BACKGROUND AND OBJECTIVES: Evidence relating the rate of change in renal function, measured as @entity3 , after antihypertensive treatment in elderly @entity0 to clinical outcome is sparse. This study characterized the rate of change in @entity3 after commencement of antihypertensive treatment in an elderly population, the factors associated with @entity3 rate change, and the rate's association with all-cause and cardiovascular mortality. DESIGN, SETTING, @entity0 , _ MEASUREMENTS: Data from the Second Australian National Blood Pressure study were used, where 6083 @entity1 @entity0 aged >= 65 years were enrolled during 1995-1997 and followed for a median of 4.1 years (in-trial). Following the Second Australian National Blood Pressure study, @entity0 were followed-up for a further median 6.9 years (post-trial). The annual rate of change in the @entity3 was calculated in 4940 @entity0 using @entity4 measurements during the in-trial period and classified into quintiles (Q) on the basis of the following @entity3 changes: rapid decline (Q1), decline (Q2), stable (Q3), increase (Q4), and rapid increase (Q5). RESULTS: A rapid decline in @entity3 in comparison with those with stable eGFRs during the in-trial period was associated with older age, living in a rural area, wider pulse pressure at baseline, receiving diuretic-based therapy, taking multiple antihypertensive drugs, and having blood pressure <140/90 mmHg during the study. However, a rapid increase in @entity3 was observed in younger @entity0 and those with a higher @entity2 level. After adjustment for baseline and in-trial covariates, Cox-proportional hazard models showed a significantly greater risk for both all-cause (hazard ratio, 1.28; 95% confidence interval, 1.09 to 1.52; P=0.003) and cardiovascular (hazard ratio, 1.40; 95% confidence interval, 1.11 to 1.76; P=0.004) mortality in the rapid decline group compared with the stable group over a median of 7.2 years after the last @entity3 measure. No significant association with mortality was observed for a rapid increase in @entity3 . CONCLUSIONS: In elderly @entity0 with treated @entity1 , a rapid decline in @entity3 is associated with a higher risk of mortality.

title: Rate of Change in Renal Function and Mortality in Elderly Treated @entity1 XXXX .

answer: @entity0


abstract: There were 30 @entity0 , under 1 yr of age, in refractory congestive @entity4 , who underwent surgical correction for @entity5 . The series was divided into two groups, depending on the type of surgical procedure performed: Group 1, 17 @entity0 end-to-end @entity2 ; Group 2, 13 @entity0 aortic angioplasty. Aortic angioplasty was carried out by three methods. Ten @entity0 had a @entity7 as described by Waldhausen in 1966. In two @entity0 a carotid artery flap angioplasty was used to enlarge a severely hypoplastic @entity6 . In one @entity0 an onlay patch of pericardium was used to relieve obstruction across a coarcted segment. Mortality rates in this series and other series from the literature are primarily dependent upon associated @entity3 . Mortality rates approach zero in @entity0 operated on for @entity5 who have no associated @entity1 . While the mortality rate was slightly lower in those @entity0 treated by some type of angioplasty, the figures are too small to be significant. In this series and other series recoarctation is far less likely to occur after @entity7 in comparison to those @entity0 undergoing end-to-end @entity2 . We would advise that in @entity0 1 yr of age, a subclavian or carotid flap angioplasty be used as a primary method of repair.

title: Methods of management and results following surgery for XXXX in infancy.

answer: @entity5


abstract: STUDY DESIGN: Retrospective study. PURPOSE: To estimate the usefulness of bone scan and @entity3 ( @entity3 ) for the diagnosis of new @entity1 in @entity4 . OVERVIEW OF LITERATURE: The diagnosis of new @entity4 requires simple X-ray and supplementary studies. METHODS: We analyzed 87 vertebrae in 44 @entity0 , who diagnosed with @entity4 using bone scan and @entity3 within 2 months interval between August 2001 and July 2008. We compared hot uptakes in bone scan with @entity3 findings such as new @entity1 , old @entity1 and @entity2 . RESULTS: Hot uptakes in bone scan was matched to 48 new @entity1 , 26 old @entity1 and 13 @entity2 in @entity3 findings. It was 55% of concordance between hot uptakes in bone scan and new @entity1 in @entity3 . The rate of new @entity1 confirmed by @entity3 according to 1 level hot uptakes in bone scan was 96%, 2 levels was 50% and 3 more levels was 36%. CONCLUSIONS: The diagnosis of new @entity1 in @entity4 requires simple X-ray and supplementary studies such as bone scan and @entity3 . We recommend more careful interpretation in multiple @entity4 @entity0 about hot uptake lesions of bone scan.

title: The comparison of bone scan and XXXX in osteoporotic compression fractures.

answer: @entity3


abstract: FDG-PET/CT is increasingly used in staging of @entity1 as single "one stop shop" method. AIM, @entity0 , METHODS: We prospectively included 104 neurological asymptomatic @entity0 (65 years, 26% @entity0 ) with primary diagnosis of @entity1 . In all @entity0 PET/CT including cerebral imaging and cerebral MRI were performed. RESULTS: Diagnosis of brain metastases (BM) was made by PET/CT in 8 @entity0 only (7.7%), by MRI in 22 (21.2%). In 80 @entity0 both PET/CT and MRI showed no BM. In 6 @entity0 (5.8%) BM were detectable on PET/CT as well as on MRI. Exclusive diagnosis of BM by MRI with negative finding on PET/CT was present in 16 @entity0 (15.4%). 2 @entity0 (1.9%) had findings typical for BM on PET/CT but were negative on MRI. With MRI overall 100 BM were detected, with PET/CT only 17 BM (p < 0.01). For the diagnosis of BM PET/CT showed a sensitivity of 27.3%, specificity of 97.6%, positive predictive value of 75% and negative predictive value of 83.3%. BM diameter on PET/CT and MRI were consistent in 43%, in 57% BM were measured larger on MRI. DISCUSSION: Compared to the gold standard of MRI for cerebral staging a considerable number of @entity0 are falsely diagnosed as free from BM by PET/CT. MRI is more accurate than PET/CT for detecting multiple and smaller BM. CONCLUSION: In @entity0 with a curative option MRI should be performed additionally to PET/CT for definitive exclusion of brain metastases.

title: XXXX . Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging.

answer: @entity1


abstract: Transforming growth factor    (TGF-  ) signaling can inhibit @entity2 growth in developing @entity2 . However, it promotes @entity2 invasiveness and @entity1 in late-stage @entity2 . A number of TGF-   gene polymorphisms have been identified that can affect the survival of @entity0 with advanced @entity3 ( @entity3 ). In this study, we investigated the association of the TGF-  1 polymorphism, @entity4 , with survival in @entity0 with advanced @entity3 . Japanese @entity0 who were treated for unresectable advanced @entity3 between April 2003 and March 2008 at Kyoto University Hospital, were enrolled in this study. Analyses of genotype associations with survival outcomes were performed using statistical tests. The median survival of @entity0 with the TT genotype was shorter, although not significantly, than that of @entity0 with either the CT or CC genotype. Based on both univariable and multivariable analyses, the TGF-  1 polymorphism, @entity4 , was not associated with prognosis. In @entity0 with a smoking status of <40 pack-years, the median survival was significantly shorter with the TT genotype than with the CT or CC genotype. Based on univariable analysis, stage IV @entity2 and the TT genotype had a significant prognostic effect on survival. Based on multivariable analysis, the TT genotype was a significantly independent prognostic factor for survival. There was no association between the TGF-  1 polymorphism, @entity4 , and survival in @entity0 with advanced @entity3 . In @entity0 with a smoking status of <40 pack-years, however, the TGF-  1 polymorphism, @entity4 , was significantly associated with the prognosis of advanced @entity3 , and the TT genotype was an independent prognostic factor for poor survival.

title: Association of the transforming growth factor   1 promoter polymorphism, @entity4 , with smoking status and survival in advanced XXXX .

answer: @entity3


abstract: Transforming growth factor    (TGF-  ) signaling can inhibit @entity2 growth in developing @entity2 . However, it promotes @entity2 invasiveness and @entity1 in late-stage @entity2 . A number of TGF-   gene polymorphisms have been identified that can affect the survival of @entity0 with advanced @entity3 ( @entity3 ). In this study, we investigated the association of the TGF-  1 polymorphism, @entity4 , with survival in @entity0 with advanced @entity3 . Japanese @entity0 who were treated for unresectable advanced @entity3 between April 2003 and March 2008 at Kyoto University Hospital, were enrolled in this study. Analyses of genotype associations with survival outcomes were performed using statistical tests. The median survival of @entity0 with the TT genotype was shorter, although not significantly, than that of @entity0 with either the CT or CC genotype. Based on both univariable and multivariable analyses, the TGF-  1 polymorphism, @entity4 , was not associated with prognosis. In @entity0 with a smoking status of <40 pack-years, the median survival was significantly shorter with the TT genotype than with the CT or CC genotype. Based on univariable analysis, stage IV @entity2 and the TT genotype had a significant prognostic effect on survival. Based on multivariable analysis, the TT genotype was a significantly independent prognostic factor for survival. There was no association between the TGF-  1 polymorphism, @entity4 , and survival in @entity0 with advanced @entity3 . In @entity0 with a smoking status of <40 pack-years, however, the TGF-  1 polymorphism, @entity4 , was significantly associated with the prognosis of advanced @entity3 , and the TT genotype was an independent prognostic factor for poor survival.

title: Association of the transforming growth factor   1 promoter polymorphism, XXXX , with smoking status and survival in advanced @entity3 .

answer: @entity4


abstract: There have been a few studies regarding detail of @entity1 in adolescents with @entity3 ( @entity3 ) as prevalence, location, and severity. The condition of @entity1 in adolescents with @entity3 was clarified based on a cross-sectional study using a questionnaire survey, targeting a total of 43,630 pupils, including all elementary school pupils from the fourth to sixth grade (21,893 pupils) and all junior high pupils from the first to third year (21,737 pupils) in Niigata City (population of 785,067), Japan. 32,134 pupils were determined to have valid responses (valid response rate: 73.7%). In Niigata City, pupils from the fourth grade of elementary school to the third year of junior high school are screened for @entity2 every year. This screening system involves a three-step survey, and the third step of the survey is an imaging and medical examination at the Niigata University Hospital. In this study, the pupils who answered in the questionnaire that they had been advised to visit Niigata University Hospital after the school screening were defined as @entity2 group (51 pupils; 0.159%) and the others were defined as No @entity2 group (32,083 pupils). The point and lifetime prevalence of @entity1 , the duration, the recurrence, the severity and the location of @entity1 were compared between these groups. The severity of @entity1 was divided into three levels (level 1 no limitation in any activity; level 2 necessary to refrain from participating in sports and physical activities, and level 3 necessary to be absent from school). The point prevalence was 11.4% in No @entity2 group, and 27.5% in @entity2 group. The lifetime prevalence was 32.9% in No @entity2 group, and 58.8% in @entity2 group. According to the gender- and school-grade-adjusted odds ratios (OR), @entity2 group showed a more than twofold elevated odds of @entity1 compared to No @entity2 group irrespective of the point or lifetime prevalence of @entity1 (OR, 2.29; P = 0.009 and OR, 2.10; P = 0.012, respectively). @entity2 group experienced significantly more severe @entity0 , and of a significantly longer duration with more frequent recurrences in comparison to No @entity2 group. @entity2 group showed significantly more @entity1 in the @entity1 in comparison to No @entity2 group. These findings suggest that there is a relationship between @entity0 around the right scapula in @entity2 group and the right rib hump that is common in @entity3 .

title: Back XXXX in adolescents with @entity3 : epidemiological study for 43,630 pupils in Niigata City, Japan.

answer: @entity0


abstract: There have been a few studies regarding detail of @entity1 in adolescents with @entity3 ( @entity3 ) as prevalence, location, and severity. The condition of @entity1 in adolescents with @entity3 was clarified based on a cross-sectional study using a questionnaire survey, targeting a total of 43,630 pupils, including all elementary school pupils from the fourth to sixth grade (21,893 pupils) and all junior high pupils from the first to third year (21,737 pupils) in Niigata City (population of 785,067), Japan. 32,134 pupils were determined to have valid responses (valid response rate: 73.7%). In Niigata City, pupils from the fourth grade of elementary school to the third year of junior high school are screened for @entity2 every year. This screening system involves a three-step survey, and the third step of the survey is an imaging and medical examination at the Niigata University Hospital. In this study, the pupils who answered in the questionnaire that they had been advised to visit Niigata University Hospital after the school screening were defined as @entity2 group (51 pupils; 0.159%) and the others were defined as No @entity2 group (32,083 pupils). The point and lifetime prevalence of @entity1 , the duration, the recurrence, the severity and the location of @entity1 were compared between these groups. The severity of @entity1 was divided into three levels (level 1 no limitation in any activity; level 2 necessary to refrain from participating in sports and physical activities, and level 3 necessary to be absent from school). The point prevalence was 11.4% in No @entity2 group, and 27.5% in @entity2 group. The lifetime prevalence was 32.9% in No @entity2 group, and 58.8% in @entity2 group. According to the gender- and school-grade-adjusted odds ratios (OR), @entity2 group showed a more than twofold elevated odds of @entity1 compared to No @entity2 group irrespective of the point or lifetime prevalence of @entity1 (OR, 2.29; P = 0.009 and OR, 2.10; P = 0.012, respectively). @entity2 group experienced significantly more severe @entity0 , and of a significantly longer duration with more frequent recurrences in comparison to No @entity2 group. @entity2 group showed significantly more @entity1 in the @entity1 in comparison to No @entity2 group. These findings suggest that there is a relationship between @entity0 around the right scapula in @entity2 group and the right rib hump that is common in @entity3 .

title: Back @entity0 in adolescents with XXXX : epidemiological study for 43,630 pupils in Niigata City, Japan.

answer: @entity3


abstract: The purpose of this study was to examine the role of dose selection on population pharmacokinetic (PK) parameter estimation using a rapid binding approximation of a @entity0 ( @entity0 ) model previously developed for @entity1 ( @entity1 ). A total of 50 replicate datasets each containing 100 subjects were created using NONMEM. The study design included IV injection of @entity1 followed by the SC route in a crossover manner, with each dose and route of administration separated by a 1,000 h washout period. Serial plasma PK samples were simulated up to 48 h for all subjects following each dose. Population mean PK parameters were re-estimated in NONMEM for each simulated dataset using the same @entity0 model after including the following doses (MIU/kg): (A) 1, 3 and 10 (original study); @entity2 MIU/kg only. Bias in the model fit was assessed by calculating the percent prediction error (PE%) for each of the population mean PK parameters relative to the estimates obtained from the fit to the 1, 3, and 10 MIU/kg doses (Case A). Relatively unbiased population mean PK parameter estimates (median PE% <8%) were obtained only when the study design included 1, 3 and a minimum higher dose of 7 MIU/kg. Bias increased for various parameters when the highest dose was less than 7 MIU/kg along with 1 and 3 MIU/kg being the low and intermediate dose levels. An increase in the bias for binding capacity, R(tot), and the equilibrium dissociation constant, K (D), was observed as the highest dose included in the dataset was reduced from 5 to 3 MIU/kg (median PE% ranged from -4.71 to -23.9% and -4.76 to -34.6%). Similar increases in the range of median PE% were also observed for other model parameters as the highest dose was reduced from 5 to 3 MIU/kg. Severely biased results were obtained from the study design that included only the 10 MIU/kg dose (Case G) suggesting that it is not sufficient to study just a high dose group. This bias was greatly reduced (median PE% <14%) for all parameters except K (D) when the 3 and 10 MIU/kg doses were co-modeled (Case F). Plots of the PE% for R(tot) and K (D) versus the molar ratio of maximum dose to R(tot) suggest that study designs should evaluate at least one @entity1 dose 3.5- to 4-fold higher than R(tot) along with the 1 and 3 MIU/kg dose levels to obtain unbiased population PK parameter estimates. In summary, for the @entity1 model and study design, dose selection influences the ability to generate relatively unbiased population mean @entity0 parameter estimates, which is based on maximum dose levels relative to R(tot). This simulation study highlights the role of dose selection in optimal study design strategies for drugs such as @entity1 that exhibit @entity0 properties.

title: Impact of dose selection on parameter estimation using a rapid binding approximation model of XXXX .

answer: @entity0


abstract: The mechanism whereby @entity3 ion ( @entity1 ) prolongs the action potential (AP) was examined by standard microelectrode techniques in papillary muscles isolated from nonreserpinized and reserpinized @entity0 hearts. First, effects of 5 and 10 mmol/l @entity1 on steady-state AP parameters, i.e. the maximum rate of rise of AP (Vmax), AP amplitude, AP duration and resting potential, were examined at stimulation rates of 0.1 to 5 Hz. Second, effects of 5 and 10 mmol/l @entity1 on nonsteady-state AP parameters, i.e. the recovery processes of Vmax, AP duration and overshoot, were examined by introducing premature responses with various diastolic intervals between the basic stimulation rate of 0.1 Hz. @entity1 prolonged the AP more in the nonreserpinized preparations than in the reserpinized ones at all stimulation rates. In both preparations, this prolongation of the AP was greater at lower rates (0.1-1 Hz) than at higher rates (2-5 Hz), but the ratio of @entity1 -treated AP duration to control one was almost the same at all stimulation rates. @entity1 slowed the recovery process of AP duration in the nonreserpinized preparations, but not in the reserpinized ones. @entity1 had no effects on the recovery processes of Vmax and overshoot in both preparations. These results suggest that: @entity1 modifies its intrinsic prolonging action of the AP by releasing @entity2 from sympathetic nerve terminals; @entity1 prolongs the AP by reducing the time-independent outward current rather than the time-dependent outward current; and a @entity1 -sensitive current does not effectively contribute to the total ionic current at the time of Vmax.

title: Effects of XXXX on the action potential duration as modified by catecholamine-releasing action in @entity0 papillary muscles.

answer: @entity3


abstract: The mechanism whereby @entity3 ion ( @entity1 ) prolongs the action potential (AP) was examined by standard microelectrode techniques in papillary muscles isolated from nonreserpinized and reserpinized @entity0 hearts. First, effects of 5 and 10 mmol/l @entity1 on steady-state AP parameters, i.e. the maximum rate of rise of AP (Vmax), AP amplitude, AP duration and resting potential, were examined at stimulation rates of 0.1 to 5 Hz. Second, effects of 5 and 10 mmol/l @entity1 on nonsteady-state AP parameters, i.e. the recovery processes of Vmax, AP duration and overshoot, were examined by introducing premature responses with various diastolic intervals between the basic stimulation rate of 0.1 Hz. @entity1 prolonged the AP more in the nonreserpinized preparations than in the reserpinized ones at all stimulation rates. In both preparations, this prolongation of the AP was greater at lower rates (0.1-1 Hz) than at higher rates (2-5 Hz), but the ratio of @entity1 -treated AP duration to control one was almost the same at all stimulation rates. @entity1 slowed the recovery process of AP duration in the nonreserpinized preparations, but not in the reserpinized ones. @entity1 had no effects on the recovery processes of Vmax and overshoot in both preparations. These results suggest that: @entity1 modifies its intrinsic prolonging action of the AP by releasing @entity2 from sympathetic nerve terminals; @entity1 prolongs the AP by reducing the time-independent outward current rather than the time-dependent outward current; and a @entity1 -sensitive current does not effectively contribute to the total ionic current at the time of Vmax.

title: Effects of @entity3 on the action potential duration as modified by catecholamine-releasing action in XXXX papillary muscles.

answer: @entity0


abstract: OBJECTIVE: Irreversible electroporation is a new ablation modality. Our purpose was to describe the MRI findings after irreversible electroporation treatment of @entity2 ( @entity2 ). SUBJECTS AND METHODS: In an 18-month period, we treated 24 @entity2 in 20 @entity0 who were not candidates for surgery. MRI was performed before and 1 month after irreversible electroporation. We used the liver-specific contrast medium gadoxetic acid. We evaluated the size, shape, signal intensity (T1-weighted, T2-weighted, and diffusion-weighted imaging), dynamic contrast enhancement pattern, and signal behavior during the liver-specific phase. Changes in the perilesional parenchyma, perfusion abnormalities, and complications were also recorded. RESULTS: According to the modified Response Evaluation Criteria in Solid Tumors system, 22 of 24 lesions had a complete response, and two lesions showed a partial response and were retreated. The lesions showed a mean size increase of 10%, with a round or oval shape. On the T1-weighted images, we observed a hyperintense core and a hypointense rim. On the T2-weighted sequences, the signal was heterogeneously hypointense. On diffusion-weighted images, 83% of lesions showed restricted diffusion, with b values of 0-800 s/mm(2), whereas in 17% of the lesions, the signal was not clearly discernible for different b values. The apparent diffusion coefficient values did not show statistically significant differences between the baseline (800-1020 * 10(-3) mm(2)/s) and the reassessment after 1 month (900-1100 * 10(-3) mm(2)/s). The @entity1 area did not show a signal increase after contrast material injection. Perfusion abnormalities, such as areas of transient hepatic intensity difference, were present in the tissue adjacent to six treated lesions. In two @entity0 , a reduced or absent concentration of the contrast medium was observed during the liver-specific phase around the ablation zone. One @entity0 had an arteriovenous shunt and another had biliary duct dilatation. CONCLUSION: MRI detects characteristic morphologic and functional changes after irreversible electroporation treatment.

title: Percutaneous Ablation Therapy of XXXX With Irreversible Electroporation: MRI Findings.

answer: @entity2


abstract: OBJECTIVE: Brucellosis is an important @entity1 , especially in developing countries, and may involve any organ, including the cardiovascular system. This study aimed to assess cardiac and endothelial functions in @entity7 @entity0 . METHODS: Seventy-three @entity0 with @entity7 and seventy-five healthy volunteers from @entity3 were enrolled between 2011 and 2013 in this cross-sectional study. Diagnosis was established by the Rose-Bengal test, positive Brucella standart tube agglutination test, and Coombs STA and/or isolation Brucella species from blood. Cases were divided into three groups: Group I; acute @entity7 , Group II; subacute @entity7 , and Group III; chronic @entity7 . Healthy individuals comprised Group IV. All @entity0 underwent transthoracic echocardiography and brachial artery @entity4 ( @entity4 ) test. RESULTS: Groups I to IV comprised 35, 18, and 20 @entity0 , and 75 controls respectively. The most frequent symptoms were @entity8 (82%), @entity2 (92%), and @entity6 (97%). Echocardiography revealed no difference among the 4 groups regarding left ventricular systolic and diastolic functions and valvular functions. Brachial artery diameter after @entity5 was significantly different among the groups (p=0.002). Post hoc test showed Group III to have significantly lower brachial artery diameter after @entity5 compared to other groups (p=0.02, p=0.004 and p=0.001, respectively). @entity4 was also significantly lower in Group III compared to Groups I, II and IV (p<0.001 for each). CONCLUSION: Brucellosis impairs endothelial functions in chronic symptomatic @entity0 without overt cardiac involvement.

title: Brucellosis impairs endothelial functions in chronic symptomatic XXXX without overt cardiac involvement.

answer: @entity0


abstract: We have asked, is @entity6 in the fed state in pregnancy due to intolerance to exogenous fat, accumulation of endogenous @entity5 , or accumulation of remnants of d < 1.006 lipoprotein metabolism? To answer these questions, we fed fat-free diets high in starch or @entity4 , or diets containing fat or fat plus @entity1 to pregnant and nonpregnant @entity0 for 12 days until gestational day 21 (term = 22 days). Blood was obtained 0, 4, or 8 hr after removal of food from the cages. Lipid concentrations were determined in chylomicrons and very low, low, and high density lipoproteins. @entity6 in pregnancy exists on both starch and @entity4 containing fat-free diets and is exaggerated 4 and 8 hr after food is removed from the cage. The @entity2 rise occurs in d < 1.006 lipoproteins. With fat feeding, chylomicron @entity2 concentrations are not significantly elevated in pregnant @entity0 , 0 or 8 hr postabsorptively despite greater food intake in pregnancy. In contrast, very low density lipoprotein (VLDL) @entity2 concentrations are elevated at all times following fat feeding in pregnant compared to nonpregnant animals. A significant contribution of lipoprotein remnants to the @entity2 rise in d < 1.006 lipoproteins seems unlikely since an isolated increase in VLDL @entity1 is not observed. No statistically significant accumulation of hepatic @entity5 occurs on any diet in pregnancy. Diet induced shifts in adipose tissue and muscle lipoprotein lipase activity are exaggerated in pregnancy while @entity7 is unaffected. Fetal weight is similar on all diets except @entity4 where weight is reduced. CONCLUSIONS: @entity6 in fed pregnant @entity0 is due to an increase in endogenous @entity5 . Remnant lipid accumulation does not appear to contribute to the endogenous @entity6 . There is no intolerance to exogenous (dietary) fat. The results are compatible with an unimpaired delivery of exogenous fat to fat oxidizing tissues thereby maximizing @entity3 availability for fetal growth.

title: Lipid metabolism in pregnancy. VIII. Effects of dietary fat versus carbohydrate on lipoprotein and hepatic lipids and tissue XXXX lipases.

answer: @entity2


abstract: BACKGROUND AND AIMS: Previous studies mostly focused on the diagnostic accuracy of @entity1 ( @entity1 ) in the diagnosis of @entity2 ( @entity2 ). We aimed to explore the clinical usefulness of @entity1 results in the diagnostic procedure of undefined @entity2 . METHODS: The retrospective analysis included @entity0 undergoing @entity1 for the diagnosis of undefined @entity2 from January 2007 to December 2010. The clinically useful @entity1 was defined as that lead to a specific histopathological diagnosis or that was consistent with the working diagnosis based on existing clinical and radiological data. RESULTS: A total of 664 @entity0 were included in the study. @entity1 failed to obtain lung parenchyma in 155 cases (23.3%). @entity1 was considered clinically helpful in 202 procedures (30.4%), including 114 cases that provided definitive histopathological diagnoses and 88 cases that were consistent with working diagnoses. Among 202 cases of clinically useful TBLBs, the majority were diagnosed as @entity4 ( @entity4 ) (67 cases, 33.2%), connective tissue disease-related @entity2 (CTD- @entity2 ) (65, 32.2%) and @entity3 ( @entity3 ) (33, 16.3%). Although @entity1 could provide definitive histopathological diagnoses in all cases diagnosed as @entity4 , only few cases of @entity3 (7, 21.2% of @entity3 diagnoses) and CTD- @entity2 (9, 13.8% of CTD-ILD diagnoses) could be identified by TBLBs. CONCLUSION: The clinical usefulness of @entity1 , in conjunction with thorough clinical and radiological data, in the diagnosis of @entity2 may be varied depending on different subtypes. The use of histopathological analysis and the type of biopsy employed should therefore be considered on a case-by-case basis.

title: The evaluation of clinical usefulness of transbrochoscopic lung biopsy in undefined XXXX : a retrospective study.

answer: @entity2


abstract: @entity8 (EA) has been shown to have antioxidant, antibacterial, and anti-inflammatory activities. In Uighur traditional medicine, Euphorbia humifusa Willd is used to treat @entity1 , and recent studies suggest that it is the EA content which is responsible for its therapeutic effect. However, the effects of EA on antifungal activity have not yet been reported. This study aimed to investigate the inhibitory effect of EA on fungal strains both in vitro and in vivo. The minimal inhibitory concentration (MIC) was determined by the National Committee for Clinical Laboratory Standards (M38-A and M27-A2) standard method in vitro. EA had a broad spectrum of antifungal activity, with MICs for all the tested dermatophyte strains between 18.75 and 58.33     g/ml. EA was also active against two Candida strains, with MICs between 25.0 and 75.0     g/ml. It was inactive against @entity5 . The susceptibility of six species of dermatophytes to EA was comparable with that of the commercial antifungal, @entity3 . The most sensitive filamentous species was @entity7 (MIC   =   18.75     g/ml). Studies on the mechanism of action using an HPLC-based assay and an enzyme linked immunosorbent assay showed that EA inhibited @entity6 biosynthesis and reduced the activity of @entity4 14a-demethylase P450 (CYP51) in the @entity7 membrane, respectively. An in vivo test demonstrated that topical administration of EA (4.0 and 8.0   mg/cm(2) ) significantly enhanced the cure rate in a @entity2 @entity0 model of @entity7 . The results suggest that EA has the potential to be developed as a natural antifungal agent.

title: Antifungal Activity of XXXX In Vitro and In Vivo.

answer: @entity8


abstract: INTRODUCTION: The aim of the present study was to evaluate the role of intravenous @entity4 in relieving the symptoms and signs of @entity1 in the emergency department setting. @entity0 AND METHODS: This was a randomized, placebo-controlled, superiority, single-blind study. @entity0 were randomized either to intravenous @entity4 (group A) or to placebo (group B), with all @entity0 receiving symptomatic therapy. The primary outcome was defined as necessity to hospitalize @entity0 who present with @entity1 in the emergency department. The secondary outcomes were (a) improvement in nystagmus, (b) improvement in postural instability, (c) lessening of @entity2 , (d) @entity3 , and (e) recovery of subjective symptoms. RESULTS: Altogether, 100 @entity0 were randomized, 51 into group A and 49 into group B. There was no difference in the hospitalization rate between groups (P=0.284). In both groups, there was a statistically significant difference in the values of all measured variables 2   h after therapy intervention compared with the baseline values. In group A, significantly fewer @entity0 had third-degree nystagmus 2   h after therapy intervention whereas the difference in group B did not reach statistical significance. After therapy, more @entity0 had first-degree nystagmus in group A as well as in group B than before the intervention. There was a significantly greater absolute difference in European Evaluation of Vertigo scale results in group A compared with group B. CONCLUSION: The value of @entity4 cannot be established, given the small sample and limitations of the present study. Some observations consistent with clinical improvement cannot exclude a true treatment effect, and further study is still warranted.

title: Intravenous @entity4 in acute management of XXXX : a randomized, placebo-controlled, single-blind trial.

answer: @entity1


abstract: INTRODUCTION: The aim of the present study was to evaluate the role of intravenous @entity4 in relieving the symptoms and signs of @entity1 in the emergency department setting. @entity0 AND METHODS: This was a randomized, placebo-controlled, superiority, single-blind study. @entity0 were randomized either to intravenous @entity4 (group A) or to placebo (group B), with all @entity0 receiving symptomatic therapy. The primary outcome was defined as necessity to hospitalize @entity0 who present with @entity1 in the emergency department. The secondary outcomes were (a) improvement in nystagmus, (b) improvement in postural instability, (c) lessening of @entity2 , (d) @entity3 , and (e) recovery of subjective symptoms. RESULTS: Altogether, 100 @entity0 were randomized, 51 into group A and 49 into group B. There was no difference in the hospitalization rate between groups (P=0.284). In both groups, there was a statistically significant difference in the values of all measured variables 2   h after therapy intervention compared with the baseline values. In group A, significantly fewer @entity0 had third-degree nystagmus 2   h after therapy intervention whereas the difference in group B did not reach statistical significance. After therapy, more @entity0 had first-degree nystagmus in group A as well as in group B than before the intervention. There was a significantly greater absolute difference in European Evaluation of Vertigo scale results in group A compared with group B. CONCLUSION: The value of @entity4 cannot be established, given the small sample and limitations of the present study. Some observations consistent with clinical improvement cannot exclude a true treatment effect, and further study is still warranted.

title: Intravenous XXXX in acute management of @entity1 : a randomized, placebo-controlled, single-blind trial.

answer: @entity4


abstract: Because of the involvement of prostaglandins in the labor mechanism, it was hypothesized that elevated @entity1 levels would presage preterm deliveries. A comparison of plasma @entity3 ( @entity4 ) levels was made between pregnant @entity0 who eventually delivered at term (N = 22) and those who delivered preterm (N = 17). Maternal blood was collected from each @entity0 at approximately 1-week intervals between 16 and 40 weeks' gestation and during labor. Mixed cord blood was also obtained at delivery. @entity4 was measured in plasma by radioimmunoassay. Plasma @entity4 concentrations did not vary throughout pregnancy. @entity4 concentrations did increase during labor, and the highest levels were found in cord blood at delivery. Mean @entity4 levels during labor and in cord blood were not significantly different between the preterm and term groups. In 1 @entity2 @entity0 the @entity4 concentration during labor was higher than that of all other @entity0 , including those who delivered at term. Excluding this @entity0 , @entity2 @entity4 concentrations were significantly lower (P less than .05) than those at term. In general, the study provides evidence that most cases of @entity2 are not characterized by elevated @entity1 levels.

title: Plasma XXXX in pregnant @entity0 with term and preterm deliveries.

answer: @entity1


abstract: Because of the involvement of prostaglandins in the labor mechanism, it was hypothesized that elevated @entity1 levels would presage preterm deliveries. A comparison of plasma @entity3 ( @entity4 ) levels was made between pregnant @entity0 who eventually delivered at term (N = 22) and those who delivered preterm (N = 17). Maternal blood was collected from each @entity0 at approximately 1-week intervals between 16 and 40 weeks' gestation and during labor. Mixed cord blood was also obtained at delivery. @entity4 was measured in plasma by radioimmunoassay. Plasma @entity4 concentrations did not vary throughout pregnancy. @entity4 concentrations did increase during labor, and the highest levels were found in cord blood at delivery. Mean @entity4 levels during labor and in cord blood were not significantly different between the preterm and term groups. In 1 @entity2 @entity0 the @entity4 concentration during labor was higher than that of all other @entity0 , including those who delivered at term. Excluding this @entity0 , @entity2 @entity4 concentrations were significantly lower (P less than .05) than those at term. In general, the study provides evidence that most cases of @entity2 are not characterized by elevated @entity1 levels.

title: Plasma @entity1 in pregnant XXXX with term and preterm deliveries.

answer: @entity0


abstract: OBJECTIVES: The purpose of this study was to describe rates and patterns of long- and short-acting alpha agonist use for @entity3 in a primary care population following Food and Drug Administration (FDA) approval of the long-acting alpha agonists @entity6 and @entity5 . METHODS: @entity0 and adolescents 4-18 years of age, who received an alpha agonist prescription between 2009 and 2011, were identified from a sample of 45 United States primary care practices in two electronic health record-based research networks. Alpha agonist receipt was identified using National Drug Codes and medication names. The proportion of subjects receiving long- and short-acting prescriptions in each year was calculated and examined with respect to reported mental health diagnoses, and whether indications for use were on-label, had evidence from clinical trials, or had no trial evidence. RESULTS: In a cohort of 282,875 subjects, 27,671 (10%) received any psychotropic medication and only 4,227 subjects (1.5%) received at least one prescription for an alpha agonist, most commonly a short-acting formulation (83%). Only 20% of alpha agonist use was on-label (use of long-acting formulations for @entity2 [ @entity2 ]). Most subjects (68%) received alpha agonists for indications with evidence of efficacy from clinical trials but no FDA approval, primarily short-acting formulations for @entity2 and @entity7 ; 12% received alpha agonists for diagnoses lacking randomized clinical trial evidence in @entity0 , including @entity1 and @entity4 , or for which there was no documented mental health diagnosis. Rates of long-acting alpha agonist use increased more than 20-fold from 0.2% to 4%, whereas rates of short-acting alpha agonist use grew only slightly between 2009 and 2011 from 10.6% to 11.3%. CONCLUSIONS: Alpha agonist use was uncommon in this population, and most subjects received short-acting forms for conditions that were off-label, but with clinical trial evidence. The safety and efficacy of use for conditions, including @entity1 and @entity4 , lacking evidence from randomized trials, warrant further investigation.

title: Changing patterns of alpha agonist medication use in XXXX and adolescents 2009-2011.

answer: @entity0


abstract: BACKGROUND: Collaboration between family caregivers and health professionals in specialised hospitals or community-based primary healthcare systems can be challenging. During the course of severe @entity1 , several health professionals might be involved at a given time, and the @entity0 's illness may be unpredictable or not well understood by some of those involved in the treatment and care. AIM: The aim of this study was to explore the experiences and expectations of family caregivers for @entity0 with @entity2 concerning collaboration with healthcare professionals. METHODS: To shed light on collaboration from the perspectives of family caregivers, we conducted an explorative, qualitative interview study with 15 adult @entity0 experienced from caring for family members in all stages of @entity2 . Data were analysed with systematic text condensation, a cross-case method for thematic analysis of qualitative data. RESULTS: We found that family caregivers approached health services hoping to understand the illness course and to share their concerns and stories with skilled and trustworthy professionals. Family caregivers felt their involvement in consultations and access to ongoing exchanges of knowledge were important factors in improved health services. They also felt that the clarity of roles and responsibilities was crucial to collaboration. CONCLUSIONS: Family caregivers should be acknowledged for their competences and should be involved as contributors in partnerships with healthcare professionals. Our study suggests that building respectful partnerships with family caregivers and facilitating the mutual sharing of knowledge may improve the coordination of care. It is important to establish clarity of roles adjusted to caregivers' individual resources for managing responsibilities in the care process.

title: Family caregivers' views on coordination of care in XXXX : a qualitative study.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVES: Identification of mutations in the downstream @entity4 ( @entity4 ) signaling pathway could provide important insights of @entity4 -targeted therapies in @entity3 . We analyzed the mutation spectra of the @entity9 / @entity6 / @entity5 and RAS/ @entity7 /MAPK pathways in @entity3 and the associations of these mutations with sites of @entity1 or recurrence. METHODS: The study population comprised 1,492 retrospectively collected stages I-IV @entity3 specimens. Tissue was obtained between 2000 and 2010 at a single hospital. We analyzed 61 hot spots using MALDI-TOF mass spectrometry for nucleic acid analysis. RESULTS: Mutations were found in the RAS pathway in 47.3% of @entity0 and in the @entity9 pathway in 14.3% of @entity0 , with 9.2% of @entity0 carrying mutations in both pathways. Both the RAS and @entity9 pathway mutations were significantly associated with proximal @entity2 , @entity2 , and microsatellite instability. @entity2 carrying a RAS pathway mutation exhibited a higher frequency of lung and peritoneal @entity1 than did @entity2 with a wild-type gene (P   =   0.025 and 0.009, respectively). @entity8 gene mutation was significantly associated with lung @entity1 (P   =   0.001). CONCLUSIONS: Somatic mutations in the RAS pathway of the @entity2 in @entity3 can influence patterns of @entity1 and recurrence.

title: Mutations in the RAS and @entity9 pathways are associated with metastatic location in XXXX .

answer: @entity3


abstract: BACKGROUND AND OBJECTIVES: Identification of mutations in the downstream @entity4 ( @entity4 ) signaling pathway could provide important insights of @entity4 -targeted therapies in @entity3 . We analyzed the mutation spectra of the @entity9 / @entity6 / @entity5 and RAS/ @entity7 /MAPK pathways in @entity3 and the associations of these mutations with sites of @entity1 or recurrence. METHODS: The study population comprised 1,492 retrospectively collected stages I-IV @entity3 specimens. Tissue was obtained between 2000 and 2010 at a single hospital. We analyzed 61 hot spots using MALDI-TOF mass spectrometry for nucleic acid analysis. RESULTS: Mutations were found in the RAS pathway in 47.3% of @entity0 and in the @entity9 pathway in 14.3% of @entity0 , with 9.2% of @entity0 carrying mutations in both pathways. Both the RAS and @entity9 pathway mutations were significantly associated with proximal @entity2 , @entity2 , and microsatellite instability. @entity2 carrying a RAS pathway mutation exhibited a higher frequency of lung and peritoneal @entity1 than did @entity2 with a wild-type gene (P   =   0.025 and 0.009, respectively). @entity8 gene mutation was significantly associated with lung @entity1 (P   =   0.001). CONCLUSIONS: Somatic mutations in the RAS pathway of the @entity2 in @entity3 can influence patterns of @entity1 and recurrence.

title: Mutations in the RAS and XXXX pathways are associated with metastatic location in @entity3 .

answer: @entity9


abstract: INTRODUCTION: Poststroke, less-severe motor impairment occurs on the ipsilesional side of body. The objective of the present study was to evaluate the effectiveness of the motor training involving the less-affected side (MTLA) in @entity1 . METHODS: This was a randomized, controlled, double-blinded pilot study conducted in the occupational therapy unit of a rehabilitation Institute. A convenience sample of 35 @entity1 subjects (mean poststroke duration, 28.76 weeks) was randomized into two groups (the experimental group: 17 and control group: 18). Thirty-two @entity0 completed the entire study protocol. The experimental group and control group were provided MTLA and neurophysiological-based conventional therapy respectively. Both the groups received 24 treatment sessions (60 minutes each) over the period of two months. The Affected side was assessed using Brunnstrom recovery stage ( @entity2 ) and Fugl-Meyer assessment (FMA) whereas the less-affected side was evaluated by Minnesota manual dexterity test (MMDT), Purdue peg board test (PPBT) and Manual Muscle Testing (MMT). RESULTS: Postintervention, the less-affected side of experimental group demonstrated significant improvement for MMDT (P = 0.003), PPBT (P = 0.01) and MMT (P   <    0.001 to 0.043) in comparison to the control group. Further, as compared to the control group, the experimental group exhibited positive significant change for the measure of affected side [ @entity2 (P <    0.001) and FMA (P <    0.001 to 0.03)] at post assessment. CONCLUSION: MTLA enhanced the muscle strength, dexterity and coordination of the less-affected side as well as the motor recovery of the affected side in poststroke hemiparetic subjects.

title: Effect of motor training involving the less-affected side (MTLA) in post- XXXX subjects: a pilot randomized controlled trial.

answer: @entity1


abstract: A prospective study of an Intracath method of diagnostic peritoneal lavage was done of 100 @entity0 with blunt @entity3 . Initial results in @entity1 confirmed the reliability and sensitivity of the technique. In @entity0 , it proved to be 96 per cent accurate. Fifty-eight @entity0 had true-positive results, and in 52 of these, subsequent laparotomy demonstrated significant hemoperitoneum and intra-abdominal injury. Six @entity0 had intra-abdominal injuries of limited significance. Thirty-eight of these @entity0 were considered to have true-negative results. In one @entity0 , false-negative, signs of @entity2 later developed, and a splenectomy was performed without incidence. There were three false-positive results. These @entity0 underwent laparotomy and recovered without a problem. The only complications noted were puncture of the urinary bladder in one @entity0 and subcutaneous infusions of lavage fluid in two @entity0 which were recognized during the procedure. Results of this study demonstrate the safety and reliability of the Intracath method of peritoneal lavage for @entity0 with blunt @entity3 .

title: Peritoneal lavage in blunt XXXX .

answer: @entity3


abstract: BACKGROUND: @entity7 ( @entity7 ) and @entity8 ( @entity8 ) are @entity6 -dependent protein deacetylases involved in the regulation of key @entity2 -associated genes. In this study we evaluated the relevance of these deacetylases in @entity1 biology. MATERIAL AND METHODS: Protein levels of @entity7 and @entity8 were determined in @entity5 ( @entity5 ) cell lines and @entity2 from 105 @entity0 . Changes in proliferation were assessed after @entity7 and @entity8 downregulation in @entity1 cell lines using siRNA-mediated technology or tenovin-1, a @entity7 and @entity8 inhibitor. RESULTS: High @entity7 and @entity8 protein levels were found in @entity5 cell lines compared with non-tumor lung epithelial cells. The expression of @entity7 and @entity8 proteins was also significantly higher in lung @entity2 than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear @entity7 staining was observed in @entity3 than in @entity4 (P=0.033). Interestingly, in @entity5 @entity0 , high @entity7 and @entity8 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high @entity7 and @entity8 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that @entity7 and/or @entity8 downregulation significantly decreased proliferation of @entity5 . CONCLUSIONS: Our results support the hypothesis that @entity7 and @entity8 have a protumorigenic role in @entity1 , promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in @entity5 @entity0 and may help to identify those @entity5 @entity0 with high risk of recurrence that could benefit from adjuvant therapy after resection.

title: Expression of sirtuin 1 and 2 is associated with poor prognosis in XXXX @entity0 .

answer: @entity5


abstract: BACKGROUND: @entity7 ( @entity7 ) and @entity8 ( @entity8 ) are @entity6 -dependent protein deacetylases involved in the regulation of key @entity2 -associated genes. In this study we evaluated the relevance of these deacetylases in @entity1 biology. MATERIAL AND METHODS: Protein levels of @entity7 and @entity8 were determined in @entity5 ( @entity5 ) cell lines and @entity2 from 105 @entity0 . Changes in proliferation were assessed after @entity7 and @entity8 downregulation in @entity1 cell lines using siRNA-mediated technology or tenovin-1, a @entity7 and @entity8 inhibitor. RESULTS: High @entity7 and @entity8 protein levels were found in @entity5 cell lines compared with non-tumor lung epithelial cells. The expression of @entity7 and @entity8 proteins was also significantly higher in lung @entity2 than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear @entity7 staining was observed in @entity3 than in @entity4 (P=0.033). Interestingly, in @entity5 @entity0 , high @entity7 and @entity8 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high @entity7 and @entity8 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that @entity7 and/or @entity8 downregulation significantly decreased proliferation of @entity5 . CONCLUSIONS: Our results support the hypothesis that @entity7 and @entity8 have a protumorigenic role in @entity1 , promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in @entity5 @entity0 and may help to identify those @entity5 @entity0 with high risk of recurrence that could benefit from adjuvant therapy after resection.

title: Expression of sirtuin 1 and 2 is associated with poor prognosis in @entity5 XXXX .

answer: @entity0


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity6 ( @entity6 ) is associated with plasma @entity2 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity6 gene in @entity0 with various forms of @entity5 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity6 gene of 313 @entity0 with @entity4 above the 95th percentile for age and sex (107 of whom had @entity4 above 875 mg/dl) and 121 @entity0 with @entity1 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity3 change. There were 13 @entity0 (12.1%) with @entity4 above 875 mg/dl and 10 @entity0 (4.9%) with moderately elevated @entity4 , who were carriers of at least one rare, non-synonymous mutation in the @entity6 gene. Of the @entity0 with @entity7 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity6 gene are frequent in @entity0 with elevated @entity4 .

title: Rare variants in the XXXX ( @entity6 ) gene are common in @entity5 but rare in @entity1 .

answer: @entity6


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity6 ( @entity6 ) is associated with plasma @entity2 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity6 gene in @entity0 with various forms of @entity5 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity6 gene of 313 @entity0 with @entity4 above the 95th percentile for age and sex (107 of whom had @entity4 above 875 mg/dl) and 121 @entity0 with @entity1 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity3 change. There were 13 @entity0 (12.1%) with @entity4 above 875 mg/dl and 10 @entity0 (4.9%) with moderately elevated @entity4 , who were carriers of at least one rare, non-synonymous mutation in the @entity6 gene. Of the @entity0 with @entity7 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity6 gene are frequent in @entity0 with elevated @entity4 .

title: Rare variants in the @entity6 ( XXXX ) gene are common in @entity5 but rare in @entity1 .

answer: @entity6


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity6 ( @entity6 ) is associated with plasma @entity2 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity6 gene in @entity0 with various forms of @entity5 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity6 gene of 313 @entity0 with @entity4 above the 95th percentile for age and sex (107 of whom had @entity4 above 875 mg/dl) and 121 @entity0 with @entity1 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity3 change. There were 13 @entity0 (12.1%) with @entity4 above 875 mg/dl and 10 @entity0 (4.9%) with moderately elevated @entity4 , who were carriers of at least one rare, non-synonymous mutation in the @entity6 gene. Of the @entity0 with @entity7 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity6 gene are frequent in @entity0 with elevated @entity4 .

title: Rare variants in the @entity6 ( @entity6 ) gene are common in XXXX but rare in @entity1 .

answer: @entity5


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity6 ( @entity6 ) is associated with plasma @entity2 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity6 gene in @entity0 with various forms of @entity5 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity6 gene of 313 @entity0 with @entity4 above the 95th percentile for age and sex (107 of whom had @entity4 above 875 mg/dl) and 121 @entity0 with @entity1 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity3 change. There were 13 @entity0 (12.1%) with @entity4 above 875 mg/dl and 10 @entity0 (4.9%) with moderately elevated @entity4 , who were carriers of at least one rare, non-synonymous mutation in the @entity6 gene. Of the @entity0 with @entity7 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity6 gene are frequent in @entity0 with elevated @entity4 .

title: Rare variants in the @entity6 ( @entity6 ) gene are common in @entity5 but rare in XXXX .

answer: @entity1


abstract: OBJECTIVE: To evaluate the population and economic impact of implementing the new Joint National Committee (JNC) or European Society of @entity3 (ESH)/European Society of Cardiology (ESC) @entity3 guidelines in the Swiss population. METHODS: Cross-sectional, population-based sample (6708 @entity0 ) collected between 2003 and 2006 in the city of Lausanne, Switzerland. Blood pressure categories were defined according to both the JNC (JNC-7 and JNC-8) and the ESH/ESC (2007 and 2013) guidelines. RESULTS: The proportion of @entity0 aged 35-60 years eligible for drug treatment was 25.6% [95% confidence interval (CI) 24.4-26.9%] and 24.8% (95% CI 23.6-26.0%) for the JNC-7 and the JNC-8 guidelines, respectively; for @entity0 aged 60-75 years, the values were 62.3% (95% CI 60.1-64.5%) and 46.8% (95% CI 44.5-49.0%), respectively. Shifting from the JNC-7 to the JNC-8 guidelines would lead to an annual saving of 163.6 million Swiss francs (187.7 million US dollars or 134.5 million European    ). The proportion of @entity0 aged 35-75 years without @entity4 , @entity1 or reported history of @entity2 and eligible for treatment was 30.2% (95% CI 29.0-31.4%) for the ESH/ESC 2007 and 2013 guidelines. For @entity0 with @entity4 , @entity1 or reported history of @entity2 , the values were 73.6% (95% CI 70.8-76.3%) and 55.6% (95% CI 52.5-58.8%), respectively. Shifting from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would lead to an annual saving of 86.9 million Swiss francs (99.5 million US dollars or 71.4 million European    ). CONCLUSION: In Switzerland, shifting from the JNC-7 to the JNC-8 guidelines or from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would decrease the prevalence of @entity0 eligible for treatment and increase the percentage of treated @entity0 within blood pressure goals. Both strategies lead to potential savings in antihypertensive drug treatment.

title: Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of XXXX /European Society of Cardiology @entity3 guidelines.

answer: @entity3


abstract: OBJECTIVE: To evaluate the population and economic impact of implementing the new Joint National Committee (JNC) or European Society of @entity3 (ESH)/European Society of Cardiology (ESC) @entity3 guidelines in the Swiss population. METHODS: Cross-sectional, population-based sample (6708 @entity0 ) collected between 2003 and 2006 in the city of Lausanne, Switzerland. Blood pressure categories were defined according to both the JNC (JNC-7 and JNC-8) and the ESH/ESC (2007 and 2013) guidelines. RESULTS: The proportion of @entity0 aged 35-60 years eligible for drug treatment was 25.6% [95% confidence interval (CI) 24.4-26.9%] and 24.8% (95% CI 23.6-26.0%) for the JNC-7 and the JNC-8 guidelines, respectively; for @entity0 aged 60-75 years, the values were 62.3% (95% CI 60.1-64.5%) and 46.8% (95% CI 44.5-49.0%), respectively. Shifting from the JNC-7 to the JNC-8 guidelines would lead to an annual saving of 163.6 million Swiss francs (187.7 million US dollars or 134.5 million European    ). The proportion of @entity0 aged 35-75 years without @entity4 , @entity1 or reported history of @entity2 and eligible for treatment was 30.2% (95% CI 29.0-31.4%) for the ESH/ESC 2007 and 2013 guidelines. For @entity0 with @entity4 , @entity1 or reported history of @entity2 , the values were 73.6% (95% CI 70.8-76.3%) and 55.6% (95% CI 52.5-58.8%), respectively. Shifting from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would lead to an annual saving of 86.9 million Swiss francs (99.5 million US dollars or 71.4 million European    ). CONCLUSION: In Switzerland, shifting from the JNC-7 to the JNC-8 guidelines or from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would decrease the prevalence of @entity0 eligible for treatment and increase the percentage of treated @entity0 within blood pressure goals. Both strategies lead to potential savings in antihypertensive drug treatment.

title: Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of @entity3 /European Society of Cardiology XXXX guidelines.

answer: @entity3


abstract: OBJECTIVE: To assess disability in @entity2 ( @entity2 ) longitudinally and to identify disease-specific determinants, after accounting for informative @entity0 dropout. METHODS: We performed a multicenter, longitudinal study of 745 @entity0 with @entity2 followed in the Canadian @entity3 Research Group registry. Disability was assessed using the Health Assessment Questionnaire (HAQ). Longitudinal changes in disability were modeled using statistical approaches accounting for various levels of @entity0 dropout. RESULTS: In all the models, disability in @entity2 worsened over time. The magnitude of the worsening was small when @entity0 dropout was assumed to be completely at random (increase in the HAQ of 0.022, 95% CI 0.002-0.042, per year). After accounting for different levels of informative @entity0 dropout, the increase in the HAQ ranged from 0.039 (95% CI 0.018-0.061) per year to 0.071 (95% CI 0.048-0.094) per year. Thus, using the most conservative of these estimates, this was equivalent to an increase in the HAQ of 0.12 over 3 years. The disease correlates found to be most closely associated with disability were @entity1 and breathing problems. CONCLUSION: Our study provides strong evidence that @entity2 causes increased disability over time, with breathing problems and disease type being the strongest predictors of disability. Statistical modeling accounting for informative @entity0 dropout is necessary to properly assess the outcomes of @entity0 followed longitudinally.

title: Disability in XXXX -- a longitudinal observational study.

answer: @entity2


abstract: In this study, @entity0 data of aquatic species in Liaohe River for heavy metal @entity1 (VI) was collected and selected. The aquatic life criteria for @entity3 in Liaohe River was derived based on these @entity0 data. Moreover, water samples of 25 sites in Liaohe River were collected, and the concentrations of @entity3 in these samples were analyzed. Finally, ecological risk assessment of @entity3 in Liaohe River was performed. Moreover, interspecies correlation estimation method (ICE) established by US EPA was used to predict the acute @entity0 of species in Liaohe River, and aquatic life criteria based on predicted @entity0 data was derived. The results showed that: the measured CMC (criteria maximum concentration), measured CCC (criteria continuous concentration) and the predicted CMC were 17. 73, 12. 15 and 13. 97   g . @entity2 , respectively. Therefore, the ICE method could be used to predict the aquatic life criteria, because the predicted criteria value was very similar to the measured criteria value. Analysis of @entity1 (V) showed that the @entity3 concentrations of the 25 sites in Liaohe River were all below Class I or Class II water quality standards (GB 3838-2002), and the water quality was in good condition. However, for the potential risk of @entity3 exposure to the aquatic life of Liaohe River, the result of ecological risk assessment showed that @entity1 (V) concentrations in 7 sites exceeded the CCC in July, and @entity3 concentrations in 6 sites exceeded the CCC in December. Therefore, unacceptable effect on aquatic species caused by @entity3 exposure might have occurred in some sites of Liaohe River.

title: [Measured and Predicted Aquatic Life Criteria and Risk Assessment of XXXX (VI) in Liaohe River].

answer: @entity1


abstract: BACKGROUND: When a @entity0 is diagnosed with @entity1 , parents are faced with the task of choosing from many different intervention options. To find information about the options available, parents turn to a number of different sources. This study explores parents' (n   =   23) intervention decision-making processes and information preferences following the diagnosis of @entity1 for their @entity0 . METHODS: Qualitative thematic analysis of verbatim transcripts from interviews and focus groups involving parents of @entity0 with an @entity1 diagnosis was undertaken. RESULTS: Analysis of the results revealed that there are concurrent emotional and pragmatic intervention 'journeys' undertaken by parents post diagnosis, which encompass the primary themes of: (1) information sources used, (2) parents' information preferences and (3) factors influencing intervention decision making. Parents described a journey from the point of diagnosis that involved seeking information on @entity1 interventions from multiple sources, with the Internet being the primary source. They were overwhelmed by the sheer volume of information available, and their preferences for information varied according to their stage in the journey post diagnosis. Parents had a 'trial and error' approach to choosing @entity1 interventions, with confidence increasing as they became more familiar with their @entity0 's condition, and had opportunities to explore numerous information sources about their @entity0 's diagnosis. While confidence increased over time, consideration of the effectiveness or evidence supporting interventions remained largely absent throughout the journey. CONCLUSION: This study highlights the need for parents of @entity0 with @entity1 to be supported to make informed intervention decisions, particularly with consideration for research evidence.

title: Intervention decision-making processes and information preferences of parents of XXXX with autism spectrum disorders.

answer: @entity0


abstract: Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of @entity2 . Rituximab, the most widely used antiCD20 antibody in routine clinical practice, led not only to improvement of progressionfree survival, but also to improvement of overall survival in previously untreated @entity0 with good performance status in combination with @entity3 and @entity1 . This regimen has become the standard treatment for @entity0 in good physical condition. Rituximab and the newest antiCD20 antibody obinutuzumab in combination with @entity4 , as compared with @entity4 alone, prolonged overall survival in previously untreated @entity0 with significant comorbidities, and the combination of antiCD20 antibody with @entity4 has become the standard regimen in this group of @entity0 . Alemtuzumab and ofatumumab improved treatment results in @entity2 . Targeted therapy with combination chemotherapy and monoclonal antibody in @entity0 with @entity2 represents a significant advance in the treatment of this disease.Key words: monoclonal antibody - rituximab - ofatumumab - alemtuzumab - obinutuzumabThis study was supported by the program PRVOUK P27/LF1/1 and grant IGA-LF-2015-001.The authors declare they have no potential conflicts of interest concerning drugs, products, or   services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 28. 7. 2015Accepted: 2. 8. 2015.

title: [Monoclonal Antibodies in the Treatment of XXXX in 2015].

answer: @entity2


abstract: Among @entity0 in general hospitals approximately one-third receive antimicrobial drugs, and @entity6 develop in 3 to 4 percent of them. These two events vary widely suggesting no constant relation, except that antibiotic use affects the etiology and course of @entity6 . There is deliberation about the benefits versus the harm of antibiotic prophylaxis. It avoids the morbidity and tissue damage from @entity3 with the least antibiotic for the shortest time and works best when the need is brief or the microbial target is a single species. Among nonsurgical @entity0 , a high risk of @entity3 results from exposure to a transmissible @entity3 , minor procedural @entity2 or increased host susceptibility. In clinical use, antimicrobial prophylaxis usually combines inefficiency with unproved efficacy. Prevention of nosocomial acquisition of @entity4 , @entity1 , @entity5 and @entity3 by antibiotic prophylaxis is ineffective. Recommendations in other conditions are derived mostly from presumed benefit, recognized failures and assessment of adverse results from drug use. Inefficient long-term prophylaxis contributes to the emergence of transmissible bacterial drug resistance. Those clinical conditions that represent need with reasonable efficiency and those that are useless and dangerous prophylactic practices should be defined. Using one and avoiding the other through education and professional discipline offers the best hope of amplifying effective antibiotic prophylaxis and minimizing unwanted effects on the recipient and hospital cohorts.

title: Considerations of antibiotic prophylaxis in nonsurgical high risk XXXX .

answer: @entity0


abstract: OBJECTIVE: To comparatively analyze the efficacy, acceptability, and tolerability of various augmentation agents in adult @entity0 with @entity12 . DATA SOURCES: An electronic literature search of PubMed, EMBASE, the Cochrane Library, Web of Science, EBSCO, PsycINFO, EAGLE, and NTIS for trials published up to December 2013 was conducted. Several clinical trial registry agencies and US Food and Drug Administration reports were also reviewed. No language, publication date, or publication status restrictions were imposed. STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents ( @entity6 , @entity1 , @entity9 , @entity8 , @entity5 , @entity7 , @entity2 , @entity11 , @entity3 , @entity4 , and @entity10 ) with each other and with placebo for adult @entity12 were included. DATA EXTRACTION: The proportion of @entity0 who responded to treatment was defined as primary efficacy, and the proportion of all-cause discontinuation and side-effects discontinuation were respectively defined as acceptability and tolerability, which were assessed with odds ratios (ORs) and a Bayesian random-effects model with 95% credible intervals (CrIs). RESULTS: A total of 48 trials consisting of 6,654 @entity0 were eligible. In terms of the primary efficacy, @entity3 (OR = 1.92; 95% CrI, 1.39-3.13), @entity6 (OR = 1.85; 95% CrI, 1.27-2.27), @entity10 (OR = 1.84; 95% CrI, 1.06-3.56), and @entity5 (OR = 1.56; 95% CrI, 1.05-2.55) were significantly more effective than placebo. Sensitivity analyses indicated that efficacy estimates for @entity6 and @entity3 were more robust than those for @entity10 and @entity5 . In terms of acceptability, no significant difference was found between active agents and placebo. In terms of tolerability, compared to placebo, @entity3 (OR = 3.85; 95% CrI, 1.92-8.33), @entity2 (OR = 3.36; 95% CrI, 1.60-8.61), @entity6 (OR = 2.51; 95% CrI, 1.11-7.69), and @entity5 (OR = 2.30; 95% CrI, 1.04-6.03) were significantly less well tolerated. CONCLUSIONS: @entity3 and @entity6 appear to be the most robust evidence-based options for augmentation therapy in @entity0 with @entity12 , but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects.

title: Comparative efficacy, acceptability, and tolerability of augmentation agents in XXXX : systematic review and network meta-analysis.

answer: @entity12


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity1 cells. However, it remains largely unknown whether schiff base @entity2 complexes induce apoptosis in @entity0 @entity1 cells. Here, we synthesized a novel schiff base @entity2 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity0 @entity3 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity5 / @entity4 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base XXXX coordination compound inhibits proliferation and induces apoptosis of @entity0 @entity3 cells.

answer: @entity2


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity1 cells. However, it remains largely unknown whether schiff base @entity2 complexes induce apoptosis in @entity0 @entity1 cells. Here, we synthesized a novel schiff base @entity2 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity0 @entity3 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity5 / @entity4 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base @entity2 coordination compound inhibits proliferation and induces apoptosis of @entity0 XXXX cells.

answer: @entity3


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity1 cells. However, it remains largely unknown whether schiff base @entity2 complexes induce apoptosis in @entity0 @entity1 cells. Here, we synthesized a novel schiff base @entity2 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity0 @entity3 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity5 / @entity4 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base @entity2 coordination compound inhibits proliferation and induces apoptosis of XXXX @entity3 cells.

answer: @entity0


abstract: OBJECTIVE: To evaluate initial experience with a custom made proximal scalloped stent graft for thoracic endovascular aortic repair (TEVAR) of @entity2 involving the arch. METHODS: Between September 2012 and November 2014, @entity0 presenting with a @entity7 ( @entity7 ) with short or angulated neck were selected for treatment by custom made proximal scalloped Relay Plus stent grafts (ABS Bolton Medical, Barcelona, Spain). Prospectively acquired data relating to @entity0 demographics, procedure details, clinical outcomes, and complications were analyzed retrospectively. RESULTS: Ten selected @entity0 (50% male, mean age 77      8 years) were treated using a thoracic custom made Relay Plus stent graft, three of whom underwent additional cervical supra-aortic trunk revascularizations. @entity7 were fusiform in four cases, saccular in three, and three @entity0 were treated for proximal type I endoleaks after previous standard TEVAR. The graft was landed in zone 2 in 3 cases, in zone 1 in 4 cases, and in zone 0 in 3 cases. The custom made scallop was designed to preserve flow in the left subclavian artery in three @entity0 , in the left common carotid artery in four, and in the innominate artery in three. No proximal @entity5 occurred and proximal sealing was achieved in all cases, with a technical success rate of 100%. All targeted vessels were patent. During a mean follow up of 12      5 months, no conversion to open surgical repair and no @entity6 occurred. One @entity0 died post-operatively from @entity4 and one @entity0 suffered a @entity1 with complete recovery. One @entity0 had a distal @entity5 on the 6 month CT scan and is scheduled for distal extension. No @entity3 , retrograde dissection and no other aortic related complications were recorded. CONCLUSIONS: Proximal scalloped stent grafts appear to be an effective additional tool for TEVAR of @entity7 when dealing with short or angulated proximal necks.

title: Proximal Scallop in XXXX Repair to Overcome Neck Issues in the Arch.

answer: @entity7


abstract: A very rare, but severe complication, occurring together with @entity7 , is the so-called @entity8 (H for haemolysis, EL for elevated liver enzymes and LP for low platelet counts). Perinatal mortality for this syndrome is estimated at 9.5% up to 60%, maternal mortality at 3.5%. We examined retrospectively 11 @entity0 of the last 5 years, presenting not only @entity2 , @entity4 and @entity1 , but also pathologically elevated data concerning transaminases, indirect @entity5 and @entity6 ; the mean value for GI in this group was 7.7 (3-11). Thrombocyte counts showed mean values of 71,000 +/- 28,500. In 9 cases the @entity0 suffered from severe upper @entity3 . Liver enzymes and @entity5 were clearly elevated. Time interval between onset of therapy and delivery was 3 days on the average, the mean gestational age at time of delivery was 34 weeks (27-39), average @entity0 weight amounted to 1,960 g (580-3,700 g). 7 of the 11 @entity0 delivered by Caesarian section (64%); perinatal, respectively neonatal 3 babies died (27%). In two cases one Caesarian section did not produce maternal complications; 3 @entity0 had to undergo a hysterectomy. This syndrome is associated with a very problematic obstetrical situation in respect of differential diagnosis, foetal outcome and the high frequency of postoperative maternal complications.

title: [ @entity8 : a rare, threatening complication in XXXX ].

answer: @entity7


abstract: A very rare, but severe complication, occurring together with @entity7 , is the so-called @entity8 (H for haemolysis, EL for elevated liver enzymes and LP for low platelet counts). Perinatal mortality for this syndrome is estimated at 9.5% up to 60%, maternal mortality at 3.5%. We examined retrospectively 11 @entity0 of the last 5 years, presenting not only @entity2 , @entity4 and @entity1 , but also pathologically elevated data concerning transaminases, indirect @entity5 and @entity6 ; the mean value for GI in this group was 7.7 (3-11). Thrombocyte counts showed mean values of 71,000 +/- 28,500. In 9 cases the @entity0 suffered from severe upper @entity3 . Liver enzymes and @entity5 were clearly elevated. Time interval between onset of therapy and delivery was 3 days on the average, the mean gestational age at time of delivery was 34 weeks (27-39), average @entity0 weight amounted to 1,960 g (580-3,700 g). 7 of the 11 @entity0 delivered by Caesarian section (64%); perinatal, respectively neonatal 3 babies died (27%). In two cases one Caesarian section did not produce maternal complications; 3 @entity0 had to undergo a hysterectomy. This syndrome is associated with a very problematic obstetrical situation in respect of differential diagnosis, foetal outcome and the high frequency of postoperative maternal complications.

title: [ XXXX : a rare, threatening complication in @entity7 ].

answer: @entity8


abstract: The stimulation of @entity0 release by the interrenal tissue of @entity2 was investigated using an in vitro preparation of the interrenals and a radioimmunoassay for determinations of @entity5 and @entity3 in the perifusate. The stimulatory activity of four different areas was tested, the pars distalis, the post- and preoptic hypothalamus, and the cerebrum. It was found that besides the pars distalis, the post- and preoptic hypothalamus exhibit stimulatory activity on the interrenals. No such activity was found in the cerebrum. There was a decrease of activity found from the pars distalis to the postoptic and then to the preoptic part of the hypothalamus. The release of both @entity1 had different sensitivity. @entity3 release was significantly elevated by all three different tissues, while the increase of the release of @entity5 was only found significant in the case of stimulation by the pars distalis. The results also make clear that the increase of the release of @entity5 is less than that of @entity3 . The ratio of @entity5 to @entity3 decreased significantly after stimulation. This points to the fact that the rate of conversion of @entity5 to @entity3 (18-hydroxylation) is stimulated more than the production of @entity5 from @entity4 .

title: The distribution of interrenal stimulating activity in the brain of XXXX .

answer: @entity2


abstract: OBJECTIVES: Work ability may be considered as an important aspect of well-being and health status. One of the most important factors in association with work ability is health-related quality of life (HRQoL). The aim of this study has been to determine the association between work ability, individual characteristics and HRQoL of female workers. MATERIAL AND METHODS: The design of this study has been cross-sectional. The @entity2 ( @entity2 ) and Short-Form General Health Survey (SF-12) questionnaires were used to collect data. Three hundred and twenty female workers were selected from food supplier factories in Karaj. One-way analysis of variance, Pearson's correlation analysis, independent sample t-test and multiple linear regression methods were used to analyze data. RESULTS: Mean (M) and standard deviation (SD) of the @entity2 stood at 35.02 and 5.57, respectively. The categories of the @entity2 for @entity0 being as follows: 8.8% poor, 62% moderate, 25.4% good and 3.7% excellent. Mean  SD for the physical component summary (PCS) and @entity1 ( @entity1 ) of quality of life was 58.84  11.12 and 57.45  9.94, respectively. There was a positive significant association between the PCS and @entity1 with the @entity2 (p = 0.0001). Workers with higher education had a better work ability (p = 0.002) and shift-work workers had a worse work ability (p = 0.03). CONCLUSIONS: Work ability of majority of @entity0 was moderate. Considering mean age of studied @entity0 (27.6 years old), this work ability is not satisfactory. Physical and mental components of the HRQoL were the important factors associated with work ability.

title: Quality of life, work ability and other important indicators of XXXX 's occupational health.

answer: @entity0


abstract: BACKGROUND: Exercise is a key component of rehabilitation for soft tissue injuries of the shoulder; however its effectiveness remains unclear. OBJECTIVE: Determine the effectiveness of exercise for @entity0 . METHODS: We searched seven databases from 1990 to 2015 for randomized controlled trials (RCTs), cohort and case control studies comparing exercise to other interventions for @entity0 . We critically appraised eligible studies using the Scottish Intercollegiate Guidelines Network (SIGN) criteria. We synthesized findings from scientifically admissible studies using best-evidence synthesis methodology. RESULTS: We retrieved 4853 articles. Eleven RCTs were appraised and five had a low risk of bias. Four studies addressed @entity1 . One study addressed nonspecific @entity0 . For variable duration @entity1 : 1) supervised strengthening leads to greater short-term improvement in @entity0 and disability over wait listing; and 2) supervised and home-based strengthening and stretching leads to greater short-term improvement in @entity0 and disability compared to no treatment. For persistent @entity1 : 1) supervised and home-based strengthening leads to similar outcomes as surgery; and 2) home-based heavy load eccentric training does not add benefits to home-based rotator cuff strengthening and physiotherapy. For variable duration low-grade nonspecific @entity0 , supervised strengthening and stretching leads to similar short-term outcomes as corticosteroid injections or multimodal care. CONCLUSION: The evidence suggests that supervised and home-based progressive shoulder strengthening and stretching are effective for the management of @entity1 . For low-grade nonspecific @entity0 , supervised strengthening and stretching are equally effective to corticosteroid injections or multimodal care. SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42013003928.

title: Is exercise effective for the management of XXXX and other soft tissue injuries of the shoulder? A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration.

answer: @entity1


abstract: Chemotherapy is an integral part of modern day treatment regimen but anticancer drugs fail to demarcate between cancerous and normal cells thereby causing severe form of systemic @entity5 . Among which @entity7 is a dreadful complication developed in @entity1 @entity0 upon cyclophosphamide (CP) therapy. @entity3 , @entity4 , and apoptosis are the major patho-mechanisms involved in CP-induced @entity7 . In the present study, we have synthesized Nano-Se, nanotechnology-based new form of elemental selenium which has significantly lower @entity5 and acceptable bioavailability. In order to meet the need of effective drugs against CP-induced adverse effects, nano selenium (Nano-Se) was tested for its possible protective efficacy on CP-induced @entity7 and @entity6 . @entity11 resulted in @entity9 which was revealed by massive histopathological changes. @entity8 was associated with oxidative stress/lipid peroxidation as evident by increased in reactive oxygen species, nitric oxide level, and malondialdehyde (MDA) formation with decreased in level of antioxidants such as reduced glutathione, @entity12 , glutathione peroxidase, superoxide dismutase, and @entity10 . Furthermore, CP at a dose of 25  mg/kg b.w. increased pulmonary DNA damage ('comet tail') and triggered DNA fragmentation and apoptosis in @entity2 @entity6 . On the other hand, Nano-Se at a dose of 2  mg  Se/kg b.w., significantly inhibited CP-induced DNA damage in bronchoalveolar lavage cells, and decreased the apoptosis and percentage of DNA fragmentation in @entity6 and also antagonized the reduction of the activities of antioxidant enzymes and the increase level of MDA. Thus, our results suggest that Nano-Se in pre- and co-administration may serve as a promising preventive strategy against CP-induced @entity7 .

title: Nano-Se attenuates cyclophosphamide-induced XXXX through modulation of oxidative stress and DNA damage in Swiss albino @entity2 .

answer: @entity8